Brian Mathie
Optometrist · Canton, OHNPI 1013953116
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $48,463 of the $68,291 with a category attached, or 71.0%. Sun Pharmaceutical Industries Inc. accounts for 77.3% of it on its own, with 27 other manufacturers making up the rest. Among optometrist clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 348 payments — averaging $196.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sun Pharmaceutical Industries Inc.$53K
- Biotissue Holdings Inc.$6K
- AbbVie$3K
- Alcon$1K
- Kala Pharmaceuticals, Inc.$934
- Ivantis, Inc$655
- plus $3K from 22 others
What the payments were for
- Consulting fees$4,9007%
- Speaking & faculty fees$48,46371%
- Travel & lodging$5,1858%
- Food & beverage$9,74414%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sun Pharmaceutical Industries Inc. | 88 | $52,779 |
| Biotissue Holdings Inc. | 29 | $5,977 |
| AbbVie(2 entities) | 61 | $3,451 |
| Alcon | 28 | $1,034 |
| Kala Pharmaceuticals, Inc. | 9 | $934 |
| Ivantis, Inc | 21 | $655 |
| Novartis | 25 | $644 |
| Bausch & Lomb Americas Inc. | 13 | $626 |
| Oyster Point Pharma, Inc. | 18 | $401 |
| Coopervision Inc. | 3 | $300 |
| Aerie Pharmaceuticals, Inc. | 6 | $263 |
| Shire North American Group Inc | 9 | $177 |
| Amgen | 2 | $146 |
| Harrow Eye, LLC | 5 | $142 |
| Dompe US, Inc. | 2 | $139 |
| Tarsus Pharmaceuticals, Inc. | 4 | $113 |
| Thea Pharma Inc. | 5 | $79 |
| Johnson & Johnson Vision Care, Inc. | 1 | $69 |
| Mallinckrodt Hospital Products Inc. | 3 | $68 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $62 |
| Astellas Pharma US Inc | 2 | $47 |
| Rayner Intraocular Lenses Limited | 3 | $47 |
| Carl Zeiss Meditec, Inc. | 1 | $38 |
| Glaukos Corporation | 1 | $30 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $29 |
| Rxsight Inc | 1 | $19 |
| NEW World Medical,inc. | 1 | $11 |
| Maculogix, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CEQUA$51,711
- Prokera$2,857
- AmnioGraft$2,857
- AmnioGuard$2,639
- RESTASIS$2,016
- EYSUVIS$819
- Hydrus Microstent$340
- INFUSE$232
- MiSight Contact Lens$218
- LUMIGAN$131
- TEPEZZA$130
- TRYPTYR$127
- Oxervate$124
- Rhopressa$118
- Rocklatan$118
- Precision7$114
- RESTASIS MULTIDOSE$113
- XIIDRA$109
- MIEBO$106
- DURYSTA$100
How this compares
$68,291 in reported general payments places this provider in the 95th percentile of 1,995 optometrist providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 251 | $111,711 |
| RestasisCyclosporine | 113 | $111,158 |
| XiidraLifitegrast | 56 | $69,789 |
| TyrvayaVarenicline Tartrate | 37 | $30,835 |
| MieboPerfluorohexyloctane/Pf | 30 | $27,953 |
| Cyclosporine | 45 | $21,677 |
| CequaCyclosporine | 31 | $18,235 |
| Brimonidine Tartrate | 193 | $17,424 |
| RocklatanNetarsudil Mesylat/Latanoprost | 32 | $10,645 |
| VyzultaLatanoprostene Bunod | 16 | $8,846 |
| CombiganBrimonidine Tartrate/Timolol | 37 | $8,810 |
| Alphagan PBrimonidine Tartrate | 31 | $7,180 |
| Loteprednol Etabonate | 47 | $5,747 |
| Latanoprost | 575 | $5,036 |
| Prednisolone Acetate | 152 | $4,157 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $3,451 | $238,859432 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta | $626 | $106,588102 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $401 | $30,83537 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $52,779 | $18,23531 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $263 | $10,64532 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $62 | $5,74747 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,995 optometrist providers in Ohio.
Other optometrist in Canton
- Michael ShaheenCanton$94K
- Adam SchmidtCanton$16K
- Mile BrujicBowling Green$1.3M
- Gregory DenaeyerColumbus$846K
- Cory LappinMontgomery$367K
- Chris SmileyColumbus$305K
- Thomas ChesterCleveland$300K
- Carly RoseCincinnati$203K
- Wendy HallierReynoldsburg$200K
- John LahrCincinnati$145K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.